Drug Profile

Apo Si K170A C76

Alternative Names: Apo-Si-K170A-C76

Latest Information Update: 03 Apr 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Interna Therapeutics
Class Antivirals; Small interfering RNA
Mechanism of Action Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I COVID 2019 infections

Most Recent Events

23 Mar 2026 Interna Therapeutics enters into a research and development agreement with University of Oxford for Apo Si K170A C76 for COVID-2019 infections (Prevention)
23 Mar 2026 Interna Therapeutics in collaboration with University of Oxford plans a phase IIa trial for COVID-2019 infections (Prevention)
31 Jul 2025 Preclinical trials in COVID-2019 infections in Israel (Intranasal), before July 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com